Limited Competition: Data Coordinating Center for the Accelerating Medicines Partnership Target Discovery and Preclinical Validation Consortium AMP-AD DCC (U24- Clinical Trial Not Allowed )

Funding Agency:
National Institutes of Health

The goal of this funding opportunity announcement is to solicit applications focused on 1) providing data enablement for the open-science, systems-biology enterprise of the AMP-AD Target Discovery and Preclinical Validation Consortiumsupported through the companion FOA (RFA-AG-18-013) and 2) sustaining and expanding the big-data infrastructure of the AMP-AD Knowledge Portal as a collaborative research platform through which members of the Consortium, researchers at large, and citizen scientists can engage in rapid translational learning and contribute to the development of predictive models of AD and AD-related dementias.  


  • Letter of Intent: January 20, 2018
  • Application Due Date(s): February 20, 2018

RFA-AG-18-014 Expiration Date February 21, 2018

Agency Website

Eligibility Requirements

Only institutions that have previously received a sub-award for data enablement of the AMP-AD Target Discovery and Preclinical Validation Project and for development of the AMP-AD Knowledge Portal (RFA-AG-13-013) are eligible to submit an application in response to this FOA.   



Amount Description

Annual direct costs are capped at $750,000.

The maximum project period is 5 years.

Funding Type





Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

February 20, 2018